Heck Capital Advisors LLC Purchases New Position in Pfizer Inc. (NYSE:PFE)

Heck Capital Advisors LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,849 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

Several other institutional investors have also modified their holdings of the stock. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $31,000. Czech National Bank lifted its holdings in shares of Pfizer by 6.9% during the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after purchasing an additional 74,737 shares during the period. Quent Capital LLC grew its position in Pfizer by 15.0% in the 3rd quarter. Quent Capital LLC now owns 15,252 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 1,987 shares during the last quarter. GAMMA Investing LLC increased its stake in Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 13,097 shares during the period. Finally, Diversified Trust Co raised its position in Pfizer by 33.8% during the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock worth $3,285,000 after buying an additional 28,658 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $26.51 on Monday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a market capitalization of $150.20 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The business has a 50 day moving average price of $26.27 and a two-hundred day moving average price of $27.86. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. Pfizer’s dividend payout ratio is currently 232.44%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.